Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
作者信息
Pijpers Judith A, Ferrari Michel D, Terwindt Gisela M
机构信息
Department of Neurology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.
出版信息
Brain. 2020 Jan 1;143(1):e6. doi: 10.1093/brain/awz368.
Abstract
摘要
相似文献
1
Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
Brain. 2020 Jan 1;143(1):e6. doi: 10.1093/brain/awz368.
2
OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
Brain. 2020 Jan 1;143(1):e5. doi: 10.1093/brain/awz366.
3
Chronic Migraine with Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol.
Headache. 2016 Feb;56(2):402-3. doi: 10.1111/head.12773.
4
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
J Headache Pain. 2015;17:1. doi: 10.1186/s10194-016-0591-3. Epub 2016 Jan 21.
5
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
J Headache Pain. 2018 Sep 26;19(1):91. doi: 10.1186/s10194-018-0921-8.
6
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
J Neurol Sci. 2013 Aug 15;331(1-2):48-56. doi: 10.1016/j.jns.2013.05.003. Epub 2013 Jun 19.
7
Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.
Expert Rev Neurother. 2018 Feb;18(2):167-176. doi: 10.1080/14737175.2018.1419867. Epub 2017 Dec 27.
8
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.
9
The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.
J Headache Pain. 2018 Jan 10;19(1):2. doi: 10.1186/s10194-017-0830-2.
10
OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Headache. 2011 Oct;51(9):1358-73. doi: 10.1111/j.1526-4610.2011.01990.x. Epub 2011 Aug 29.
引用本文的文献
1
Medication overuse headache: a review of current evidence and management strategies.
Front Pain Res (Lausanne). 2023 Aug 8;4:1194134. doi: 10.3389/fpain.2023.1194134. eCollection 2023.
本文引用的文献
1
OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.
Brain. 2020 Jan 1;143(1):e5. doi: 10.1093/brain/awz366.
2
Pathophysiology, prevention, and treatment of medication overuse headache.
Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4.
3
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Brain. 2019 May 1;142(5):1203-1214. doi: 10.1093/brain/awz052.
4
Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project.
Cephalalgia. 2019 Feb;39(2):274-285. doi: 10.1177/0333102418786265. Epub 2018 Jul 8.
5
Botulinum toxins for the prevention of migraine in adults.
Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2.
6
Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial.
Cephalalgia. 2018 Feb;38(2):225-236. doi: 10.1177/0333102417737779. Epub 2017 Oct 19.
7
Chronic migraine: risk factors, mechanisms and treatment.
Nat Rev Neurol. 2016 Aug;12(8):455-64. doi: 10.1038/nrneurol.2016.93. Epub 2016 Jul 8.
8
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Cephalalgia. 2016 Aug;36(9):875-86. doi: 10.1177/0333102416636843. Epub 2016 Mar 16.
9
Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2016 May;15(6):555-65. doi: 10.1016/S1474-4422(16)00017-X. Epub 2016 Mar 2.
10
Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect.
Aesthet Surg J. 2016 Apr;36(4):482-7. doi: 10.1093/asj/sjv208. Epub 2016 Jan 17.
Zotero 插件